Rating Change
William Blair analysts initiated coverage on Immunome, Inc. (NASDAQ:IMNM) with a rating of Outperform on October 16, 2026.
new coverageNASDAQ:IMNM
William Blair Initiates Coverage on Immunome, Inc. (IMNM) with Outperform
William Blair analysts initiated coverage on Immunome, Inc. (NASDAQ:IMNM) with a rating of Outperform on October 16, 2026.
At publication ·
What changed
Immunome, Inc. (NASDAQ:IMNM) · new coverage
- Firm
- William Blair
- Rating
- Outperform
- Price at event
- $16.47
- Market capitalization
- $1.8B
At a glance
Key takeaways
- William Blair initiated Outperform coverage on Immunome Inc. (IMNM) on October 16, 2026, as the healthcare company trades at $16.47 with a $1.8B market cap.
Market Context
Immunome, Inc. operates in the Healthcare sector. The stock currently trades at $16.47 with a market capitalization of $1.8B.
Analyst coverage from William Blair provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Immunome, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Immunome, Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 16, 2026 | William Blair | Outperform | N/A |
| Oct 01, 2026 | Stifel | Hold | N/A |
| Sep 21, 2026 | Alliance Global Partners | Buy | N/A |
| Sep 10, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 12, 2026 | Wedbush | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View IMNM Stock Page
Frequently Asked Questions
What does the Outperform rating mean for IMNM?
A rating of Outperform from William Blair reflects the analyst's outlook on Immunome, Inc. (NASDAQ:IMNM). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the IMNM forecast page.